Brainsway (NASDAQ:BWAY) Downgraded to “Hold” Rating by Zacks Research

Brainsway (NASDAQ:BWAY) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Tuesday,Zacks.com reports.

Other research analysts have also issued research reports about the stock. Weiss Ratings reiterated a “buy (b-)” rating on shares of Brainsway in a research note on Tuesday, July 21st. BTIG Research lifted their target price on shares of Brainsway from $18.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Brainsway in a report on Friday, July 17th. New Street Research reaffirmed a “buy” rating on shares of Brainsway in a research note on Friday, July 24th. Finally, Wall Street Zen upgraded Brainsway from a “hold” rating to a “buy” rating in a report on Sunday, August 2nd. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $16.33.

Brainsway Trading Up 10.8%

Shares of NASDAQ BWAY opened at $16.60 on Tuesday. Brainsway has a one year low of $6.25 and a one year high of $17.40. The business has a 50-day moving average price of $15.08 and a two-hundred day moving average price of $14.33. The firm has a market capitalization of $666.16 million, a PE ratio of 47.43 and a beta of 1.24.

Brainsway (NASDAQ:BWAY) last issued its earnings results on Wednesday, August 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.04. The company had revenue of $17.11 million for the quarter, compared to the consensus estimate of $16.54 million. Brainsway had a return on equity of 12.28% and a net margin of 15.68%. Research analysts anticipate that Brainsway will post 0.33 EPS for the current year.

Institutional Trading of Brainsway

Several large investors have recently added to or reduced their stakes in the business. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Brainsway during the 1st quarter worth $40,000. Ballast Advisors LLC acquired a new stake in shares of Brainsway in the 1st quarter valued at $55,000. Raymond James Financial Inc. bought a new stake in Brainsway in the second quarter worth $85,000. Bank of America Corp DE bought a new stake in Brainsway in the third quarter worth $107,000. Finally, Royal Bank of Canada increased its position in Brainsway by 1,145.9% during the fourth quarter. Royal Bank of Canada now owns 8,410 shares of the company’s stock worth $160,000 after buying an additional 7,735 shares during the last quarter. 30.11% of the stock is owned by institutional investors.

Brainsway News Roundup

Here are the key news stories impacting Brainsway this week:

• Positive Sentiment: Quarterly earnings beat expectations: BrainsWay reported second-quarter EPS of $0.14, versus the $0.10 analyst consensus, while revenue of $17.11 million exceeded estimates of $16.54 million. Revenue increased 35% year over year to a record level, and the company posted a 15.68% net margin. BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Revenue guidance was raised or reaffirmed above consensus: Management guided for fiscal 2026 revenue of $68 million to $70 million, compared with the $67.8 million consensus estimate. The outlook supports expectations for continued demand for BrainsWay’s noninvasive deep transcranial magnetic stimulation systems. BrainsWay Earnings Report and Conference Call
• Positive Sentiment: Analyst price target increased: BTIG Research raised its target from $18 to $20 and maintained a Buy rating, implying additional upside based on the referenced $16.60 share price. BrainsWay Price Target Raised by BTIG
• Neutral Sentiment: Momentum is strong, but valuation warrants attention: BWAY is trading near its one-year high and above its 50-day and 200-day moving averages. However, its price-to-earnings ratio of 47.43 leaves the stock sensitive to any slowdown in growth or future earnings disappointments. Brainsway Sets New 1-Year High Following Strong Earnings
• Neutral Sentiment: Reported short interest was listed as zero shares, so the data does not indicate meaningful short-covering pressure or a significant short-interest overhang.

Brainsway Company Profile

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices.